by The Worldwide Antimalarial Resistance Network (WWARN) AS-AQ Study Group including Diap G, Kiechel JR, Sharma B. BMC Medicine 2015, doi: 10.1186/s12916-015-0301-z.
Summary: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. The impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria was investigated using pooled patient data by the Worldwide Antimalarial Resistance Network (WWARN). There was substantial variation in the total dose of amodiaquine administered in different ASAQ combination regimens. Fixed dose AS-AQ combinations ensure optimal dosing and provide higher antimalarial treatment efficacy than the loose individual tablets in all age categories.